HEMA and DI-HEMA-TMHDC – new restrictions?
The Cosmetic Ingredient Review (CIR) Expert Panel has assessed the safety of Methacrylate ester monomers and concluded that they were safe as cosmetic ingredients, when used in nail enhancement products and labelled to avoid skin contact. Nevertheless, the CIR Expert Panel expressed concern regarding the strong sensitization and cross- or co-reactivity potential of these ingredients.

Hydroxyethylmethacrylate (HEMA) and other methacrylate ester monomers (e.g. Di-HEMA Trimethylhexyl Dicarbamate (Di-HEMA-TMHDC), Ethoxyethyl Methacrylate, Hydroxypropyl Methacrylate, Isobornyl Methacrylate, Isobutyl Methacrylate, among others) are used as film forming agents in cosmetics and personal care products, specifically in nail enhancement products to build or lengthen the nail. They are viscous liquids that result from reaction between methacrylic acid with the appropriate alcohol and that polymerize readily when exposed to UV-light. [1]

The Cosmetic Ingredient Review (CIR) Expert Panel has assessed the safety of Methacrylate ester monomers and concluded that they were safe as cosmetic ingredients, when used in nail enhancement products and labelled to avoid skin contact. Nevertheless, the CIR Expert Panel expressed concern regarding the strong sensitization and cross- or co-reactivity potential of these ingredients.  [2]

In 2017, the European Commission’s Scientific Committee on Consumer Safety (SCCS) issued an opinion regarding the safety of HEMA and Di-HEMA TMHDC and its sensitization. On this report, the SCCS concluded that “HEMA and Di-HEMA-TMHDC, when applied appropriately to the nail plate at concentrations of up to 35% and 99%, respectively as part of an artificial nail modelling system, are not likely to pose a risk of sensitization, provided that their use is restricted to the nail plate only and contact with the adjacent skin avoided”. The SCCS also concluded that these two compounds are weak to moderate sensitizers and that its incorrect use or inappropriate application might pose a risk of sensitization. [3]

In 2016, because of the several cases of allergic reactions to HEMA and Di-HEMA-TMHDC, the Swedish authorities withdrew and prohibited the use of these two substances on their market, according to Article 27 (Safeguard clause) of Regulation (EC) No 1223/2009 on cosmetic products. Sweden considered that a range of nail polishes (which are hardened with the use of a LED lamp after application) could lead to contact allergy and result in damage to nails and/or hands and, therefore, pose a serious risk for consumers. A notification of these products was made in the Rapid Alert System for Non-Food Products (RAPEX – Alert number A12/1226/14) system. [3,4]

The European Commission has prepared a regulatory proposal and submitted it to the World Trade Organization (March 26th, 2020), with a consultation period ending on May 26th (2020). In this draft amendment to Annex III of the Regulation (No 1223/2009), the European Commission proposed rules restricting the use of HEMA and Di-HEMA in nail products to professional only under the European Union cosmetic products Regulation. This regulatory proposal restricts nail products containing HEMA and Di-HEMA-TMHDC to professional use only and the warnings “for professional use only” and “can cause an allergic reaction” should be added on the package. This amendment to Annex III of the Regulation on cosmetic products is expected to be adopted in the 4th quarter of 2020. [5]

The European Commission shall grant transition periods for cosmetic companies and the compliance of their nail products. Six months after the date of entry into force of the amendment, products containing HEMA and Di-HEMA-TMHDC and not complying with the conditions “shall not be placed on the Union market”. Nine months after the date of entry into force of the amendment, products containing HEMA and Di-HEMA-TMHDC and not complying with the conditions “shall not be made available on the Union market”. This means that after the first six months period, cosmetic products containing these ingredients can not be imported/distributed but they can be sold if they are already in the market. [5]

References:

  1. Cosing – European Commision database for information on cosmetic substances and ingredients – https://ec.europa.eu/growth/tools-databases/cosing/
  2. Cosmetic Ingredient Review (CIR) Expert Panel – Final Report of the Safety Assessment of Methacrylate Ester Monomers Used in Nail Enhancement Products  – https://online.personalcarecouncil.org/ctfa-static/online/lists/cir-pdfs/pr339.pdf
  3. Scientific Committee on Consumer Safety (SCCS) – Opinion on the safety of cosmetic ingredients HEMA and Di-HEMA Trimethylhexyl Dicarbamate, Submission I, (Sensitisation only), 2017 – https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_214.pdf
  4. The Rapid Alert System for Non-Food Products (RAPEX)  – Alert number: A12/1226/14 – https://ec.europa.eu/consumers/consumers_safety/safety_products/rapex/alerts/?event=viewProduct&reference=A12/1226/14&lng=en
  5. https://images.chemycal.com/Media/Files/TBT/20_2198_01_e.pdf
  6. World Trade Organization – Notification G/TBT/N/EU/707

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »